JPMorgan Healthcare Conference Opens on the 13th...Announcement of K-bio, including Samsung Biologics and Celltrion, is underway

Jan 07, 2025

JPMorgan Healthcare Conference Opens on the 13th...Announcement of K-bio, including Samsung Biologics and Celltrion, is underway
◇ John Lim, CEO of Samsung Biologics, who made the presentation at the last year 'JP Morgan Healthcare Conference'. Photo =Samsung Biologics



Major domestic pharmaceutical and bio companies will participate in the world's largest bio-investment event 'JP Morgan Healthcare Conference' to be held in San Francisco from the 13th to the 16th (local time). Samsung Biologics, Celltrion, Bridge Biotherapeutics, and Lotte Biologics will present the presentation.

John Lim, CEO of Samsung Biologics, will present on the 14th at the Grand Ballroom of The Westin St. Francis, the main venue of the event, under the theme of '4E Excellence (△Customer Excellence), △Excellence (Operation Excellence), △High Quality Excellence, and △Excellence (People Excellence)'. It will introduce this year's business plan, mid- to long-term vision, and corporate growth background, promote the competitiveness of commissioned development production (CDMO) through investor meetings, and focus on strengthening networking to expand its business.

Celltrion Chairman Seo Jeong-jin and the eldest son Seo Jin-seok, CEO of the management division, plan to introduce the achievements and visions of new drug development such as antibody drug conjugate (ADC) anticancer drug pipeline. It is also expected to mention Celltrion BioSolutions, a subsidiary of CDMO, which was launched in December last year.




Bridge Biotherapeutics will be led by CEO of Jungkyu Lee. Introduce the company's major R&D challenges, such as idiopathic pulmonary fibrosis treatment candidates 'BBT-877', and announce future corporate growth strategies. It will also start consultations with global Big Pharma to explore technology transfer contracts for the candidate material.

James Park, the new CEO of Lotte Biologics, will introduce the construction status of Songdo Bio Campus and the direction of the project.

In addition, beauty medical device company Clasis and medical aesthetic company Hugel will also present at this year's conference.




There are also many companies seeking to strengthen their competitiveness through business partnering meetings.

Onconic Therapeutics, which developed the 37th new drug in Korea, the treatment for gastroesophageal reflux disease 'Jacubo', plans to hold meetings with global pharmaceutical and investment companies and introduce new drug pipelines. DX&VX is also focusing on attracting funds from global investment companies by promoting R&D achievements and new pipelines. ENCEL plans to introduce CDMO technology for cell gene therapy and promote discussions on exporting new drug pipeline technology.

Meanwhile, more than 550 pharmaceutical, bio, and healthcare companies and more than 8,000 participants are expected to gather at the conference, which marks its 43rd anniversary this year. Global big pharma such as GlaxoSmithKline, Eli Lilly and AstraZeneca are also scheduled to announce.






This article was translated by Naver AI translator.